# EDGAR Filing Document

**Accession Number:** 0001750149
**File Stem:** 0001193125-23-023821
**Filing Date:** 2023-2
**Character Count:** 2586
**Document Hash:** 5c60fb646b8d6159ac77e3ae827c1c71
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-023821.hdr.sgml**: 20230308

**ACCESSION NUMBER**: 0001193125-23-023821

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230203

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inhibikase Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001750149
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 3350 RIVERWOOD PARKWAY SE, SUITE 1900
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30339
- **BUSINESS PHONE:** 678-392-3419

**MAIL ADDRESS:**
- **STREET 1:** 3350 RIVERWOOD PARKWAY SE, SUITE 1900
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30339

**Inhibikase Therapeutics, Inc.** 

3350 Riverwood Parkway SE, Suite 1900

Atlanta, GA 30339

February 3, 2023

<u>VIA EDGAR</u> 

Securities and Exchange Commission

Division of Corporation Finance

Office of Trade & Services

100 F Street, N.E.

Washington, D.C. 20549-3720

Attention: Daniel Crawford

Re: Inhibikase Therapeutics, Inc.

Registration Statement on Form S-1

Filed February 2, 2023

File No. 333-269521

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Inhibikase Therapeutics, Inc. (the "**Company**") hereby requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-269521) (the "**Registration Statement**") be accelerated so that the Company's Registration Statement will become effective on **Tuesday, February 7, 2023, at 3:00 p.m.** (Eastern Time), or as soon thereafter as practicable.

Please feel free to direct any questions or comments concerning this request to Merrill M. Kraines, Esq. at (212) 547-5616 or Todd Kornfeld, Esq. at (212) 547-5890 of McDermott Will & Emery LLP.

The Company understands that the staff of the United States Securities and Exchange Commission will consider this request as confirmation by the Company that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.

---

| | |
|:---|:---|
| **INHIBIKASE THERAPEUTICS, INC.** | **INHIBIKASE THERAPEUTICS, INC.** |
| By: | /s/ Milton H. Werner |
|  | Name: Milton H. Werner, Ph.D. |
|  | Title: President and Chief Executive Officer |

---

cc: Merrill M. Kraines, McDermott Will & Emery LLP

Todd Kornfeld, McDermott Will & Emery LLP